Symptom Burden and Unmet Supportive Care Needs in Lung Cancer Patients Undergoing First or Second Line Immunotherapy
Doctors are recruiting patients receiving care for lung cancer at the Wake Forest Baptist Comprehensive Cancer Center asking about needs and experiences during immunotherapy. Immunotherapy is a new treatment for lung cancer. The research is to better understand patients' perspectives on what immunotherapy is like and will provide important information to help understand the symptoms patients experience, the impact of treatment on daily life, ways that people adapt to the challenges of treatment, and services that may help people live better during treatment.
Checked against the public recordLast updated Jul 24, 2020 · Source: ClinicalTrials.gov
What this study is about
- Purpose
- Not specified
- Study type
- Observational
- Phase
- Not applicable
- Sponsor
- Wake Forest University Health Sciences
- Interventions being studied
- Not specified
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
Inclusion Criteria: * Histologically or cytologically confirmed stage IV (per AJCC 7th edition) non-small cell lung cancer. * Receiving first or second line immunotherapy. * ECOG Performance status of 0-3. * English-speaking Exclusion Criteria: * Unable to provide informed consent
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- Laurie E SteffenWinston-Salem, North Carolina
- Wake Forest University Health SciencesWinston-Salem, North Carolina
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Jul 24, 2020. Always confirm current availability with the study team.